Molteni

Madison Realty Capital Originates $100 Million Loan for 18-Story RAMSA-Designed Luxury Residence Overlooking Central Park

Retrieved on: 
Monday, August 9, 2021
Zero, Molteni, Madison Avenue, GLOBE, Contract, Industry, Commercial, Partnership, Solomon R. Guggenheim, Solution, LinkedIn, List of Guggenheim Museums, Financial services

To date, the property has presold four units including both penthouse units, representing 42% of the project, with all contracts signed post-COVID.

Key Points: 
  • To date, the property has presold four units including both penthouse units, representing 42% of the project, with all contracts signed post-COVID.
  • The 18-story residential project has 11 full floor units, one duplex penthouse and one triplex penthouse with outdoor terraces offering views of Central Park.
  • Centrally located with easy access to nearby transit, the residence is near the Guggenheim Museum and close to high-end retail shops along Madison Avenue.
  • We selected Madison Realty Capital again because of their certainty of execution, and our track record of success together, said Scott Shnay of CBSK Ironstate.

Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon

Retrieved on: 
Monday, October 26, 2020
Companies, Titan Pharmaceuticals, Bankruptcy, Corporate finance, Titan, Molteni, Restructuring, Economy of India

The debt was secured with a lien on all assets of Titan.

Key Points: 
  • The debt was secured with a lien on all assets of Titan.
  • Under the terms of the agreement, Molteni and Horizon agreed to settle the approximately $5.2 million of outstanding indebtedness in exchange for the payment by Titan of a total of $1.6 million in cash to Horizon and Molteni, the transfer of certain Probuphine assets to Molteni, including certain equipment, inventory and non-U.S. Probuphine intellectual property, and the termination of Titan's rights to future payments under its asset purchase, supply and support agreement with Molteni.
  • "Reaching agreement on the settlement of the outstanding debt is a major step in the restructuring of Titan, and we appreciate the timely action and cooperation of Molteni and Horizon in accomplishing this goal," said Dr. DeVarney, President and Chief Operating Officer of Titan.
  • Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura long-term, continuous drug delivery technology.

SHIONOGI AND MOLTENI CONCLUDE A CONTRACT FOR THE COMMERCIALIZATION OF RIZMOIC® (NALDEMEDINE), AN OPIOID-INDUCED CONSTIPATION THERAPEUTIC AGENT IN ITALY AND POLAND

Retrieved on: 
Wednesday, May 22, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Research, Science, Shionogi, Molteni, Companies, Economy of Japan

View the full release here: https://www.businesswire.com/news/home/20190521005648/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190521005648/en/
    Shionogi has built a strong heritage in research-based medicine.
  • The companys research and development efforts target pain/central nervous system as one of its priority areas in the mid-term business plan.
  • According to this contract, Molteni will distribute and sell RIZMOIC in Italy and Poland and Shionogi will co-promote the product in Italy with Molteni.
  • The co-promotion of Shionogi and Molteni in Italy offers a synergic partnership to maximise the value of existing commercial structures.